CRISPR Therapeutics
CRSP
CRSP
405 hedge funds and large institutions have $2.5B invested in CRISPR Therapeutics in 2023 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 154 increasing their positions, 101 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
15% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 53
19% less capital invested
Capital invested by funds: $3.07B → $2.5B (-$575M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
405
Holding in Top 10
3
Calls
$80.5M
Puts
$91.5M
Top Buyers
| 1 | +$15.4M | |
| 2 | +$13M | |
| 3 | +$10.2M | |
| 4 |
IHAM
Integral Health Asset Management
New York
|
+$9.04M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.7M |
Top Sellers
| 1 | -$16.6M | |
| 2 | -$12.9M | |
| 3 | -$11M | |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$9.06M |
| 5 |
Renaissance Technologies
New York
|
-$7.47M |